HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.2%

Neg 0% Neu 90.2% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.